BioLineRx (BLRX) Corporate Presentation summary

Strategic partnerships and licensing

• Secured exclusive licensing agreements for APHEXDA (motixafortide) with Gamida Cell (global, excluding Asia and solid tumors) and Gloria Biosciences (Asia), with up to $287 million in commercial milestones and tiered royalties on sales ranging from 18% to double digits.

• Established a joint venture with Hemispherian AS to develop GLIX1 for glioblastoma and other cancers, with BioLineRx managing and funding development and an increasing economic stake up to 70%.

Pipeline and clinical development

• APHEXDA (motixafortide) is FDA-approved for stem cell mobilization in multiple myeloma and is in Phase 2b for solid tumors, including pancreatic cancer.

• GLIX1, a first-in-class oral TET2 enhancer, is set to begin Phase 1/2a trials in glioblastoma in Q1 2026, with strong preclinical efficacy and safety, and potential for broad cancer applications.

• Motixafortide is being evaluated in combination immunotherapy regimens for pancreatic ductal adenocarcinoma (PDAC), with promising pilot phase results and a randomized Phase 2b trial underway.

GLIX1 mechanism and potential

• GLIX1 restores TET2 activity, causing DNA breaks that selectively kill cancer cells while sparing healthy tissue, and shows efficacy across multiple cancer cell lines.

• Demonstrated strong blood-brain barrier penetration and efficacy in temozolomide-resistant glioblastoma models.

• Shows synergy with PARP inhibitors, potentially expanding their use to HR-proficient cancers.

• Holds orphan drug designation from FDA and EMA, with patents valid until at least 2040.